The FDA Wants Food Companies to Start Phasing Out All Artificial Dyes
Some synthetic food dyes have been linked in studies to hyperactivity in people with ADHD, and cancer and tumor growth in lab rats.
Naturally derived dyes like vegetable juices and flower extracts are being suggested for potential use in lieu of artificial food dyes.The Food and Drug Administration (FDA) announced an attempt to phase out artificial dyes from the food supply. The FDA will revoke authorization for two rarely used food colorings, ask food manufacturers to phase out six other popular synthetic dyes, and move up the timeline for removing FD&C Red No. 3. But the announcement may do little to get artificial dyes out of foods, as most of the synthetic food dyes used today would only be subject to a voluntary removal.
Related: Food Additives to Watch Out For—and Where You'll Find Them
Artificial food dyes are petroleum-based products that add or enhance color in ultra-processed foods. They're basically the reason why candy is, well, candy-colored, in bright rainbow shades. But synthetic food dyes aren't just relegated to sweets or obviously dyed foods. They can be used to make subtle color shifts in everything from beef jerky to barbecue sauces to salad dressings to give them a more palatable hue.
Artificial food dyes have been a subject of concern. Several studies have linked artificial food dyes to issues like hyperactivity in people with ADHD, and some animal studies found potential links to cancer and some synthetic dyes, according to the Center for Science in the Public Interest (CSPI). Red No. 3 was banned from cosmetics in 1990 as it was shown to cause cancer in lab rats—but that was decades before the phase-out from foods began earlier this year.
Several different tactics are being used in this announcement, and some have more teeth than others.
The two food colorings that will have their authorization revoked are Citrus Red No. 2 and Orange B—and revoking authorization ensures these dyes are off the market. However, Citrus Red No. 2 is currently only used for dyeing the skins of oranges, and it is used in such small amounts that the health risk is minimal. Orange B was once used to color hot dogs and sausages, but it hasn't been used in decades, after the FDA proposed (but never finalized) a ban in 1978, according to CSPI. "The only real regulatory moves here are to move to ban two rarely used dyes, Citrus Red 2 and Orange B, 'within the coming months,'" says Peter G. Lurie, president of the CSPI, in a statement.
There are six dyes the FDA would like to phase out with a voluntary "understanding" with food manufacturers:
FD&C Green No. 3
FD&C Red No. 40
FD&C Yellow No. 5
FD&C Yellow No. 6
FD&C Blue No. 1
FD&C Blue No. 2
But because it's an "understanding," food manufacturers can ignore it—and some manufacturers have already come out with statements defending the safety of these food dyes. This suggests that some food companies may ignore the FDA's recommendations. "The ingredients used in America's food supply have been rigorously studied following an objective science and risk-based evaluation process and have been demonstrated to be safe," says Melissa Hockstad, president and CEO of the Consumer Brands Association, a lobbying organization that represents U.S. packaged food manufacturers, in a statement.
FD&C Red No. 3 was scheduled to be removed from foods and oral drugs by 2028, but the FDA announced that they plan to shorten the deadline for companies to remove the dye from their foods—with no specific timeline announced.
Related: 8 Red Flags to Look Out for on Food Labels, According to Nutrition Experts
The FDA suggests replacing artificial food dyes with natural options—which could include extracts and juices from vegetables, fruits, flowers, and minerals. The FDA plans to fast-track research into alternative food dyes such as calcium phosphate, Galdieria extract blue, gardenia blue, and butterfly pea flower extract.
In general, new products to the market may be the first to see these changes, as food companies may add the natural dyes to them before they start changing older food formulations. But because food manufacturers aren't legally required to remove the commonly used artificial food colorants from their foods, the government may need to revoke authorization down the line to actually get them out of the food supply.
In general, highly processed foods, such as snack foods, candy, baked goods, and soft drinks, tend to feature high quantities of artificial dyes. (Those bright reds and neon greens in everything from Flamin' Hot Cheetos to M&Ms come from synthetic food dyes.)
To get a sense of what foods may have high levels of these food dyes, you can use the Environmental Working Group's Food Scores Tool, where you can search by product or ingredient to look for specific food dyes in the foods you eat. Products that contain synthetic dyes need to disclose them on their labels, so you can also review the foods in your pantry and fridge to see if they contain the six food dyes that the government is hoping manufacturers will remove from foods.
Read the original article on Real Simple
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Epoch Times
6 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
Yahoo
12 hours ago
- Yahoo
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data